506 Episodes

  1. S12 Ep29: Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

    Published: 26/03/2025

  2. S12 Ep28: Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD

    Published: 24/03/2025

  3. S12 Ep28: Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD

    Published: 20/03/2025

  4. S12 Ep27: Venetoclax Plus Pegcrisantaspase Induces Remissions in R/R AML: With Ashkan Emadi, MD, PhD

    Published: 17/03/2025

  5. S12 Ep26: FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD

    Published: 13/03/2025

  6. S12 Ep25: Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD

    Published: 12/03/2025

  7. S12 Ep24: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

    Published: 11/03/2025

  8. S12 Ep23: Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc

    Published: 10/03/2025

  9. S12 Ep22: FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD

    Published: 6/03/2025

  10. S12 Ep21: Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

    Published: 4/03/2025

  11. S12 Ep20: FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD

    Published: 3/03/2025

  12. S12 Ep19: FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

    Published: 27/02/2025

  13. S12 Ep18: Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

    Published: 26/02/2025

  14. S12 Ep17: Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO

    Published: 24/02/2025

  15. S12 Ep16: DA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD

    Published: 20/02/2025

  16. S12 Ep15: Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

    Published: 17/02/2025

  17. S12 Ep14: FDA Approval Insights: Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

    Published: 13/02/2025

  18. S12 Ep13: Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD

    Published: 10/02/2025

  19. S12 Ep12: Advances in RAS-Mutant PDAC Management Emphasize the Importance of Biomarker Testing: With Heinz-Josef Lenz, MD

    Published: 6/02/2025

  20. S12 Ep10: Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD

    Published: 3/02/2025

7 / 26

Visit the podcast's native language site